Content
Frontiers of Medicine >> 2023, Volume 17, Issue 2 doi: 10.1007/s11684-023-0985-y
Progress and challenges in RET-targeted cancer therapy
Abstract
Keywords
pralsetinib ; selpercatinib ; RET-alteration ; lung cancer ; thyroid cancer ; tumor-agnostic therapy ; drug resistance
Content